指南与共识骨质疏松与钙磷/甲状旁腺

绝经后女性骨质疏松症药物治疗:内分泌学会临床实践指南

Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline.
指南 / 共识 · J Clin Endocrinol Metab · 2019-01-01

该指南由内分泌学会制定,针对绝经后女性骨质疏松症的药物治疗提出四项管理原则:应使用国别评估工具确定未来骨折风险以指导决策;治疗计划需纳入患者偏好;所有药物治疗均应配合营养、生活方式干预和跌倒预防;多种药物可降低骨折风险且风险获益可接受。

要点

  • 使用国别评估工具确定绝经后女性未来骨折风险以指导治疗决策。
  • 治疗计划应纳入患者偏好,并考虑依从性、持续性和风险获益。
  • 所有药物治疗均应配合营养、生活方式干预和跌倒预防。

核心结论

  • 绝经后女性骨质疏松症的药物治疗应基于国别骨折风险评估工具、患者偏好以及营养生活方式干预和跌倒预防的综合管理。

研究设计与样本

  • 内分泌学会制定临床实践指南,基于临床试验证据和临床经验,并考虑患者偏好、依从性和持续性数据以及患者和提供者视角的风险获益。

主要发现

  • 写作委员会就四项管理原则达成共识:使用国别评估工具确定骨折风险、纳入患者偏好、营养生活方式干预和跌倒预防应伴随所有药物治疗、多种药物可降低骨折风险且风险获益和安全性可接受。

关键数值与推荐

  • 未来骨折风险应使用国别特异性评估工具确定以指导决策。
  • 患者偏好应纳入治疗计划。
  • 营养和生活方式干预及跌倒预防应伴随所有药物治疗方案以降低骨折风险。
  • 多种药物治疗能够降低有风险绝经后女性的骨折率,且风险获益和安全性可接受。

临床怎么用

  • 临床中应使用国别骨折风险评估工具评估绝经后女性骨折风险,结合患者偏好制定治疗计划,并在所有药物治疗中配合营养、生活方式干预和跌倒预防。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective is to formulate clinical practice guidelines for the pharmacological management of osteoporosis in postmenopausal women. CONCLUSIONS: Evidence from clinical trials and insights from clinical experience with pharmacologic therapies for osteoporosis were critically evaluated in formulating this guideline for the management of postmenopausal osteoporosis. Patient preferences, data on adherence and persistence, and risks and benefits from the patient and provider perspectives were also considered in writing committee deliberations. A consensus by the Writing Committee members was achieved for four management principles: (i) The risk of future fractures in postmenopausal women should be determined using country-specific assessment tools to guide decision-making. (ii) Patient preferences should be incorporated into treatment planning. (iii) Nutritional and lifestyle interventions and fall prevention should accompany all pharmacologic regimens to reduce fracture risk. (iv) Multiple pharmacologic therapies are capable of reducing fracture rates in postmenopausal women at risk with acceptable risk-benefit and safety profiles.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Eastell R, Rosen CJ, Black DM, et al. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab. 2019. PMID: 30907953. doi:10.1210/jc.2019-00221

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。